Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients

Saved in:
Bibliographic Details
Published inJournal of neurology, neurosurgery and psychiatry Vol. 84; no. 12; pp. 1407 - 1409
Main Authors Keung, Benison, Robeson, Kimberly R, DiCapua, Daniel B, Rosen, Jennifer B, O'Connor, Kevin C, Goldstein, Jonathan M, Nowak, Richard J
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group Ltd 01.12.2013
BMJ Publishing Group LTD
Subjects
Adult
Antibodies, Monoclonal, Murine-Derived - adverse effects
Antibodies, Monoclonal, Murine-Derived - therapeutic use
Autoantibodies - immunology
Drug Resistance - drug effects
Female
Humans
Male
Myasthenia
Myasthenia Gravis - drug therapy
Myasthenia Gravis - immunology
Neuroimmunology
Neuromuscular
Receptor Protein-Tyrosine Kinases - antagonists & inhibitors
Receptor Protein-Tyrosine Kinases - immunology
Receptors, Cholinergic - immunology
Retrospective Studies
Rituximab
Treatment Outcome
Neuroimmunology
Myasthenia
Neuromuscular
Online AccessGet full text

Cover

More Information
Bibliography:ark:/67375/NVC-CWMK1CN3-Z
ArticleID:jnnp-2012-303664
PMID:23761915
href:jnnp-84-1407.pdf
istex:069643CD64268A806B7727E75309796D80B9E2BF
local:jnnp;84/12/1407
SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0022-3050
1468-330X
DOI:10.1136/jnnp-2012-303664